| Literature DB >> 27129967 |
Fenella D Halstead1,2,3, Joanne E Thwaite4, Rebecca Burt5,3, Thomas R Laws4, Marina Raguse6, Ralf Moeller6, Mark A Webber2,3, Beryl A Oppenheim5,2.
Abstract
UNLABELLED: The blue wavelengths within the visible light spectrum are intrinisically antimicrobial and can photodynamically inactivate the cells of a wide spectrum of bacteria (Gram positive and negative) and fungi. Furthermore, blue light is equally effective against both drug-sensitive and -resistant members of target species and is less detrimental to mammalian cells than is UV radiation. Blue light is currently used for treating acnes vulgaris and Helicobacter pylori infections; the utility for decontamination and treatment of wound infections is in its infancy. Furthermore, limited studies have been performed on bacterial biofilms, the key growth mode of bacteria involved in clinical infections. Here we report the findings of a multicenter in vitro study performed to assess the antimicrobial activity of 400-nm blue light against bacteria in both planktonic and biofilm growth modes. Blue light was tested against a panel of 34 bacterial isolates (clinical and type strains) comprising Acinetobacter baumannii, Enterobacter cloacae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae, and Elizabethkingia meningoseptica All planktonic-phase bacteria were susceptible to blue light treatment, with the majority (71%) demonstrating a ≥5-log10 decrease in viability after 15 to 30 min of exposure (54 J/cm(2) to 108 J/cm(2)). Bacterial biofilms were also highly susceptible to blue light, with significant reduction in seeding observed for all isolates at all levels of exposure. These results warrant further investigation of blue light as a novel decontamination strategy for the nosocomial environment, as well as additional wider decontamination applications. IMPORTANCE: Blue light shows great promise as a novel decontamination strategy for the nosocomial environment, as well as additional wider decontamination applications (e.g., wound closure during surgery). This warrants further investigation. © Crown copyright 2016.Entities:
Mesh:
Year: 2016 PMID: 27129967 PMCID: PMC4907187 DOI: 10.1128/AEM.00756-16
Source DB: PubMed Journal: Appl Environ Microbiol ISSN: 0099-2240 Impact factor: 4.792
Clinical and control isolates used in this study
| Study identifier | Organism | Description |
|---|---|---|
| ACI_616 | QEHB clinical outbreak isolate | |
| ACI_618 | QEHB clinical outbreak isolate | |
| ACI_642 | QEHB clinical outbreak isolate | |
| ACI_648 | QEHB clinical outbreak isolate | |
| ACI_659 | QEHB clinical outbreak isolate | |
| ACI_665 | QEHB clinical outbreak isolate | |
| ACI_671 | QEHB clinical outbreak isolate | |
| ACI_672 | QEHB clinical outbreak isolate | |
| ACI_698 | QEHB clinical outbreak isolate | |
| ACI_AYE | MPR clinical isolate (unique) | |
| ACI_C60 | NCTC 13424 (unique) | |
| ACI_19606 | ATCC 19606 (unique) | |
| ENTCL_525 | QEHB clinical isolate | |
| ENTCL_801 | QEHB clinical isolate | |
| ENTCL_804 | QEHB clinical isolate | |
| STEMA_529 | QEHB clinical isolate | |
| STEMA_551 | QEHB clinical isolate | |
| STEMA_558 | QEHB clinical isolate | |
| PSE_568 | QEHB clinical isolate | |
| PSE_PA01 | ATCC 15692 | |
| PSE_6749 | NCTC 6749 | |
| PSE_1054 | QEHB clinical burn isolate | |
| PSE_1586 | QEHB clinical burn isolate | |
| EKIN_502 | QEHB clinical isolate | |
| EC_073 | EPEC CFT_073 | |
| EC_042 | EAEC_042 | |
| MDR_A | CPE | QEHB clinical isolate |
| MDR_B | CRE | QEHB clinical isolate |
| MRSA_508 | QEHB clinical isolate | |
| MRSA_520 | QEHB clinical isolate | |
| MRSA_531 | QEHB clinical isolate | |
| MSSA_10788 | NCTC 10788 | |
| MSSA_F77 | NCTC 8532 | |
| EFM_513 | QEHB clinical isolate | |
| MSSA_29213 | ATCC 29213 | |
| MSSA_10442 | NCTC 10442 | |
| MSSA_33807 | ATCC 33807 | |
| MSSA_4163 | NCTC 4163 |
MPR, Ministry of Research, Paris; CPE, carbapenemase-producing Enterobacteriaceae; NDM-1, New Delhi metallo-β-lactamase; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase.
FIG 1Survival of planktonic bacteria after exposure to 400-nm blue light. (A) Acinetobacter baumannii strains are represented as follows: ACI_616, closed circles; ACI_618, open circles; ACI_AYE, closed triangles; ACI_665, open triangles; ACI_19606, closed inverted triangles; ACI_648, open inverted triangles; ACI_659, closed diamonds; ACI_C60, open diamonds; ACI_671, closed squares; ACI_672, open squares; ACI_698, closed hexagons; and ACI_642, open hexagons. (Note that the hexagons are behind the other symbols.) (B) Staphylococcus aureus strains are represented as follows: MSSA _10788, open circles; MSSA_F77, closed triangles; MRSA_520, closed squares; MRSA_531, open triangles; and MRSA_508, closed circles. (C) Stenotrophomonas maltophilia strains are represented as follows: STEMA_ 558, triangles; STEMA_551, circles; and STEMA_529, squares. (D) Enterobacter cloacae strains are represented as follows: ENTCL_804, circles; ENTCL_801, triangles; and ENTCL_525, squares. (E) Pseudomonas aeruginosa strains are represented as follows: PSE_1586, closed circles; PSE_PAO1, open circles; PSE_568, closed triangles; PSE_1054, closed squares; and PSE_6479, open squares. (F) Other strains are represented as follows: E. coli EC_042, open circles; E. coli EC_073, closed circles; K. pneumoniae MDR-A, open squares; K. pneumoniae MDR-B, closed squares; Elizabethkingia meningoseptica EKIN_502, open triangles; and Enterococcus faecium EFM_513, open inverted triangles. Data are averages ± standard deviations (n = 3).
Antimicrobial effects of blue light on planktonic cells
| Isolate | Exposure time (min) | Irradiance (mW/cm2) | Dose (J/cm2) | Log10 reduction | LD37 value | LD90 value | |
|---|---|---|---|---|---|---|---|
| ACI_616 | 30 | 60 | 108 | 7.06 | 0.006 | 21 ± 2 | 27 ± 2 |
| ACI_618 | 30 | 60 | 108 | 5.78 | 0.007 | 55 ± 4 | 59 ± 3 |
| ACI_642 | 30 | 60 | 108 | 6.73 | 0.006 | 9 ± 1 | 16 ± 2 |
| ACI_648 | 30 | 60 | 108 | 6.14 | 0.007 | 21 ± 2 | 29 ± 3 |
| ACI_659 | 30 | 60 | 108 | 6.55 | 0.006 | 8 ± 1 | 16 ± 2 |
| ACI_665 | 30 | 60 | 108 | 6.14 | 0.006 | 7 ± 1 | 12 ± 1 |
| ACI_671 | 30 | 60 | 108 | 6.34 | 0.006 | 25 ± 2 | 32 ± 4 |
| ACI_672 | 30 | 60 | 108 | 6.22 | 0.006 | 16 ± 2 | 24 ± 2 |
| ACI_698 | 30 | 60 | 108 | 6.39 | 0.008 | 9 ± 1 | 14 ± 2 |
| ACI_AYE | 30 | 60 | 108 | 6.70 | 0.006 | 10 ± 1 | 16 ± 2 |
| ACI_C60 | 30 | 60 | 108 | 6.76 | 0.007 | 7 ± 1 | 14 ± 1 |
| ACI_19606 | 30 | 60 | 108 | 6.81 | 0.006 | 7 ± 1 | 13 ± 1 |
| ENTCL_525 | 100 | 60 | 360 | 6.76 | 0.006 | 113 ± 12 | 136 ± 19 |
| ENTCL_801 | 180 | 60 | 648 | 6.61 | 0.009 | 212 ± 20 | 246 ± 25 |
| ENTCL_804 | 160 | 60 | 576 | 6.24 | 0.007 | 258 ± 18 | 306 ± 24 |
| STEMA_529 | 30 | 60 | 108 | 7.21 | 0.006 | 7 ± 1 | 12 ± 2 |
| STEMA_551 | 30 | 60 | 108 | 2.97 | 0.006 | 26 ± 3 | 48 ± 5 |
| STEMA_558 | 30 | 60 | 108 | 7.33 | 0.006 | 8 ± 1 | 18 ± 2 |
| PSE_568 | 30 | 60 | 108 | 6.48 | 0.002 | 6 ± 1 | 12 ± 2 |
| PSE_PA01 | 30 | 60 | 108 | 5.59 | 0.001 | 6 ± 1 | 17 ± 3 |
| PSE_6749 | 30 | 60 | 108 | 6.55 | 0.009 | 7 ± 1 | 13 ± 2 |
| PSE_1054 | 30 | 60 | 108 | 6.01 | 0.002 | 9 ± 1 | 15 ± 2 |
| PSE_1586 | 30 | 60 | 108 | 6.07 | 0.002 | 13 ± 2 | 22 ± 2 |
| EKIN_502 | 15 | 60 | 54 | 6.79 | 0.006 | 1 ± 0.5 | 4 ± 3 |
| EC_073 | 30 | 60 | 108 | 4.71 | 0.006 | 56 ± 4 | 64 ± 7 |
| EC_042 | 30 | 60 | 108 | 1.55 | 0.006 | 74 ± 8 | 85 ± 9 |
| MDR_A | 140 | 60 | 504 | 6.88 | 0.002 | 124 ± 18 | 159 ± 25 |
| MDR_B | 140 | 60 | 504 | 6.61 | 0.007 | 185 ± 16 | 219 ± 22 |
| MRSA_508 | 30 | 60 | 108 | 6.17 | 0.002 | 12 ± 1 | 21 ± 3 |
| MRSA_520 | 15 | 60 | 54 | 6.82 | 0.002 | 1 ± 0.5 | 5 ± 1 |
| MRSA_531 | 30 | 60 | 108 | 6.41 | 0.001 | 7 ± 1 | 15 ± 2 |
| MSSA_10788 | 80 | 60 | 288 | 7.07 | 0.001 | 99 ± 12 | 118 ± 15 |
| MSSA_ F77 | 30 | 60 | 108 | 6.76 | 0.006 | 3 ± 1 | 12 ± 2 |
| EFM_513 | 180 | 60 | 648 | 1.86 | 0.007 | 277 ± 16 | 393 ± 20 |
| Additional | |||||||
| ATCC 29213 | 30 | 60 | 108 | 6.76 | 0.002 | 5 ± 1 | 15 ± 2 |
| NCTC 10442 | 30 | 60 | 108 | 6.69 | 0.002 | 8 ± 1 | 20 ± 2 |
| ATCC 33807 | 80 | 60 | 288 | 7.01 | 0.002 | 15 ± 2 | 40 ± 5 |
| NCTC 4163 | 80 | 60 | 288 | 6.07 | 0.003 | 38 ± 5 | 71 ± 6 |
Values are means ± standard deviations.
Yellow pigmentation.
Orange pigmentation.
FIG 2Comparison of blue light LD90 values between strains and species. Each individual circle represents the average LD90 for each strain ± the standard deviations (n = 3). The average LD90 values for the species are shown by horizontal lines.
FIG 3(A) Correlation between survival of planktonic S. aureus strains following blue light exposure and cell pigmentation. Orange carotenoid-producing strains are represented as follows: MSSA_4163, closed circles; MSSA_33807, closed inverted triangles; and MSSA_10788, closed triangles. Yellow non-carotenoid-producing strains are represented as follows: MSSA_10442, open circles; MSSA_F77, open squares; MRSA_520, open diamonds; MRSA_531, open inverted triangles; MRSA_508, open triangles; and MSSA_29213, open hexagons. Data are averages ± standard deviations (n = 3). (B) Comparison of blue light LD90 values between yellow- and orange-pigmented S. aureus strains. Each individual circle represents the average LD90 for each strain ± the standard deviation (n = 3). The average LD90 values for yellow- and orange-pigmented strains are shown by horizontal lines.
FIG 4Graphs showing the biofilm seeding results for all isolates. Optical density on the y axis refers to the average biofilm seeding for the isolates tested after exposure to blue light at the range of durations tested (in minutes) on the x axis. The positive control was to the average biofilm seeding of the dark-incubated, non-blue-light-exposed isolates. The negative control was to a negative (broth-only) control. The error bars represent the standard errors.
Average percent change in biofilm seeding in isolates exposed to blue light compared to nonexposed dark-incubated controls
Shading denotes reductions of at least 80% in biofilm seeding compared to the positive control. ^, P value = 0.15.